XDx, Inc. Files Registration Statement for Proposed Initial Public Offering
BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc. announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock. Copies of the XDx, Inc. S-1 Registration Statement can be accessed over the Internet through the SEC's Web site at edgar.sec.gov. All shares of the common stock to be sold in this offering are proposed to be sold by XDx, Inc.
XDx, Inc. is a molecular diagnostics company focused on the discovery, development and commercialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases.
J.P. Morgan Securities Inc. and Morgan Stanley & Co. Incorporated are acting as joint book-running managers, with Piper Jaffray & Co. and JMP Securities LLC acting as co-managers. The number of shares to be offered and the price range have not yet been determined. This offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this offering may be obtained from: J.P. Morgan Securities Inc.’s prospectus department at 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, or Morgan Stanley & Co. Incorporated’s prospectus department at 180 Varick Street, New York, NY 10014 or by email at email@example.com.
A registration statement relating to these securities has been filed with the SEC, but it has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time that the registration statement becomes effective. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction.
This news release contains certain forward-looking statements that involve risks and uncertainties. Forward-looking statements include XDx, Inc.’s plans to sell securities in an initial public offering. Such statements are only predictions and actual results may differ materially from those anticipated in these forward-looking statements.